181 related articles for article (PubMed ID: 15782689)
1. [Direct reporting of side effects by the patient: favourable experience in the first year].
van Grootheest AC; Passier JL; van Puijenbroek EP
Ned Tijdschr Geneeskd; 2005 Mar; 149(10):529-33. PubMed ID: 15782689
[TBL] [Abstract][Full Text] [Related]
2. Contribution of pharmacists to the reporting of adverse drug reactions.
van Grootheest AC; van Puijenbroek EP; de Jong-van den Berg LT
Pharmacoepidemiol Drug Saf; 2002; 11(3):205-10. PubMed ID: 12051119
[TBL] [Abstract][Full Text] [Related]
3. Do pharmacists' reports of adverse drug reactions reflect patients' concerns?
van Grootheest K; van Puijenbroek EP; de Jong-van den Berg LT
Pharm World Sci; 2004 Jun; 26(3):155-9. PubMed ID: 15230363
[TBL] [Abstract][Full Text] [Related]
4. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
5. [Adverse events following vaccination reported to the Netherlands Pharmacovigilance Center Lareb in 2004-2006].
Labadie J; van Grootheest AC
Ned Tijdschr Geneeskd; 2007 Dec; 151(49):2738-42. PubMed ID: 18225798
[TBL] [Abstract][Full Text] [Related]
6. A pharmaceutical manufacturer's perspective on reporting adverse drug experiences.
Sullivan JW
Am J Hosp Pharm; 1990 Jun; 47(6):1342-5. PubMed ID: 2368728
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
[TBL] [Abstract][Full Text] [Related]
8. Pharmacovigilance: characteristics of the most widely used drugs in Bulgaria.
Getov I; Dimitrova Z
Cent Eur J Public Health; 1999 Aug; 7(3):133-6. PubMed ID: 10499144
[TBL] [Abstract][Full Text] [Related]
9. HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre.
de Langen JJ; van Puijenbroek EP
Neth J Med; 2006 Oct; 64(9):334-8. PubMed ID: 17057271
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and quality of adverse drug reaction reports by pharmacists in Norway.
Gedde-Dahl A; Harg P; Stenberg-Nilsen H; Buajordet M; Granas AG; Horn AM
Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):999-1005. PubMed ID: 17457794
[TBL] [Abstract][Full Text] [Related]
11. National adverse drug reaction reporting. 1984-1989.
Faich GA
Arch Intern Med; 1991 Aug; 151(8):1645-7. PubMed ID: 1872669
[TBL] [Abstract][Full Text] [Related]
12. [The incidence of drug side effects with reference to organ systems. Experience of the spontaneous reporting system of the Swiss Drug Side Effect Center and Comprehensive Drug Monitoring].
Kuhn M; Hartmann K; Maibach R; Capaul R; Gartmann JC
Ther Umsch; 1993 Jan; 50(1):8-12. PubMed ID: 8378869
[TBL] [Abstract][Full Text] [Related]
13. The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: case-control study.
van Hunsel F; Talsma A; van Puijenbroek E; de Jong-van den Berg L; van Grootheest K
Pharmacoepidemiol Drug Saf; 2011 Mar; 20(3):286-91. PubMed ID: 21351310
[TBL] [Abstract][Full Text] [Related]
14. [Reasons to report or not report side effects of drugs to the national monitoring system in the Netherlands].
van Riemsdijk MM; Herings RM; Rawlins MD; Stricker BH
Ned Tijdschr Geneeskd; 1995 Nov; 139(45):2306-8. PubMed ID: 7501063
[TBL] [Abstract][Full Text] [Related]
15. Scientific challenges in postmarketing surveillance of ocular adverse drug reactions.
Fraunfelder FW; Fraunfelder FT
Am J Ophthalmol; 2007 Jan; 143(1):145-149. PubMed ID: 17188050
[TBL] [Abstract][Full Text] [Related]
16. Quality of adverse drug experience reports submitted by pharmacists and physicians to the FDA.
Ahmad SR; Freiman JP; Graham DJ; Nelson RC
Pharmacoepidemiol Drug Saf; 1996 Jan; 5(1):1-7. PubMed ID: 15088271
[TBL] [Abstract][Full Text] [Related]
17. Post Launch Monitoring of food products: what can be learned from pharmacovigilance.
van Puijenbroek EP; Hepburn PA; Herd TM; van Grootheest AC
Regul Toxicol Pharmacol; 2007 Mar; 47(2):213-20. PubMed ID: 17204356
[TBL] [Abstract][Full Text] [Related]
18. [Retrospective study of adverse drug reactions in the elderly: experience of regional center for pharmacovigilance].
Bruneau S; Bruhat C; Lagarce L; Lainé-Cessac P
Therapie; 2001; 56(6):785-91. PubMed ID: 11878111
[TBL] [Abstract][Full Text] [Related]
19. Expectations of general practitioners and specialist doctors regarding the feedback received after reporting an adverse drug reaction.
Cornelissen L; van Puijenbroek E; van Grootheest K
Pharmacoepidemiol Drug Saf; 2008 Jan; 17(1):76-81. PubMed ID: 17987591
[TBL] [Abstract][Full Text] [Related]
20. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience.
Blenkinsopp A; Wilkie P; Wang M; Routledge PA
Br J Clin Pharmacol; 2007 Feb; 63(2):148-56. PubMed ID: 17274788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
